Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of solid tumors. Spago Nanomedical´s share is listed on Nasdaq First North Growth Market (ticker: SPAGO). For further information, see www.spagonanomedical.se. FNCA Sweden AB is the Certified Adviser of the company, +46 8 528 00 399, info@fnca.se.

Cmed, established for 20 years, is a global technology-led full services CRO specializing in complex disease areas, particularly oncology, immuno-oncology, cell therapy and other specialty therapeutics areas. Cmed has built a reputation for delivering these clinical trials with expertise, and a personalized, flexible approach, and a mission to contributing to the development of innovative medicines for the benefits of the patients.  Cmed has a strong data management and statistics heritage. As well as being a Functional Service Provider of these services, via its Cmed Technology business (part of Cmed Group) Cmed has developed and uses an advanced, enterprise, cloud based clinical data system, encapsia®. encapsia delivers a complete solution to gather and manage multiple live clinical data sources and apply real-time data management, sophisticated visualizations, analytics and AI. Client benefits include informed trial progress, deep insights into their data to support timely management decisions and particularly relevant with the disruption caused by the COVID-19 pandemic, able to support remote, decentralized and virtual trial conduct. Cmed is an Alten company and operates with ALTEN Clinical Group. For more information,  visit www.cmedresearch.com and www.encapsia.com or contact Info@cmedgroup.com.